Private Trust Co. NA boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 1.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,927 shares of the medical instruments supplier’s stock after buying an additional 61 shares during the period. Private Trust Co. NA’s holdings in Becton, Dickinson and Company were worth $676,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Saudi Central Bank purchased a new position in Becton, Dickinson and Company in the 1st quarter valued at $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $27,000. Alpine Bank Wealth Management purchased a new stake in Becton, Dickinson and Company during the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC increased its holdings in shares of Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth $31,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.
Becton, Dickinson and Company Trading Up 2.1%
Shares of BDX stock opened at $189.20 on Friday. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The company has a 50 day moving average price of $190.60 and a 200 day moving average price of $184.63. The stock has a market capitalization of $54.23 billion, a P/E ratio of 34.03, a price-to-earnings-growth ratio of 1.48 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.
Becton, Dickinson and Company Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 74.82%.
Insider Transactions at Becton, Dickinson and Company
In other news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders sold 1,838 shares of company stock valued at $348,392. 0.36% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Royal Bank Of Canada reissued a “sector perform” rating and set a $211.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday. Morgan Stanley increased their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Piper Sandler restated a “neutral” rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Argus increased their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $205.40.
Get Our Latest Stock Report on BDX
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- What is Insider Trading? What You Can Learn from Insider Trading
- Johnson & Johnson’s M&A Strategy Is the Real Story for Investors
- What is a Low P/E Ratio and What Does it Tell Investors?
- Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
- Using the MarketBeat Dividend Yield Calculator
- Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.